Sun Pharmaceutical Industries (SUNPHARMA) Investor presentation summary

Business overview and global presence

• Operates in over 100 countries with a diversified portfolio including innovative medicines, branded generics, generics, and APIs.

• Largest pharmaceutical company in India with 8.3% market share and 13th largest in US generics market.

• 40 manufacturing facilities across six continents, many approved by global regulators.

• Over 43,000 employees worldwide, with a strong focus on quality compliance.

• Expanding presence in ex-US developed markets and emerging markets.

Financial performance and growth

• FY25 sales reached Rs 520 Bn, with a 19% CAGR in sales from FY10 to FY25.

• EBITDA margin at 29% in FY25, with adjusted net profit margin at 22.8%.

• Market capitalization of US $47 Bn as of December 2025.

• Free cash flow CAGR of 24% from FY10 to FY25.

• Strong return ratios: ROCE at 20.5% and ROE at 17.4% in FY25.

Revenue composition and business segments

• India formulations contributed 33%, US formulations 31%, emerging markets 18%, ROW 14%, and API & others 4% of FY25 sales.

• US business is the 13th largest in generics, with 665 ANDAs and 71 NDAs filed.

• India business leads with 31 brands in the top 300 and a strong chronic and acute segment presence.

• Emerging markets span over 80 countries, focusing on branded generics and local manufacturing.

• ROW includes Western Europe, Canada, Japan, Australia, New Zealand, and Israel, with a diverse product basket.